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COMBINED SURGICAL ABLATION WITH SUPERPULSED
CO2 LASER FOR TREATMENT OF FACIAL BASAL CELL
CARCINOMA
Eiad khoury *
Abstract
Basal cell carcinoma (BCC) is the most common skin cancers in face region. The most concern for surgeons is success of treatment with high cure rate
and good cosmetic result. There are several methods for treatment , including laser therapy.
The objectives of the present study were to evaluate the healing of wounds (recurrence and cosmetic outcome) after treatment by surgical ablation and
irradiation by superpulsed mode of laser CO2.
A total of 18 patients with BCC, age between 58-71 years, from both gender (7 males and 11 females) were included in the study. The tumorous mass was
ablated firstly, then the tumor bed was irradiated using 5-8W Pulsed CO2 laser. The wounds were left open to secondary epithelization.
Recurrence and cosmetic outcomes were observed after one year follow-up. The mean age of the participants was 66 years (range 58-71 years). The
mean size (maximal diameter of lesion) was 9.3 mm (range: 7.2-11.3mm). 12 tumors (66.6%) were of the superficial type, 6 tumors (33.3%) were of
the nodular type.
No recurrence was observed one year after surgery. Slight scar was found in 3 cases (16.6%). There were no complications during the wound healing
period .
The present study showed that the surgical ablation combined with superpulsed CO2 laser is an effective option to treat BCC and to achieve high cure
rates and good esthetic outcomes.
Keywords: Laser surgery - facial skin tumor – healing - superpulsed CO2 laser – basal cell carcinoma.
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ABLATION CHIRURGICALE COMBINÉE AVEC LE LASER CO2
SUPERPULSÉ POUR LE TRAITEMENT DU CARCINOME FACIAL BASOCELLULAIRE
Résumé
Le carcinome basocellulaire (CBC) est le cancer de la peau le plus fréquent au niveau de la région de la face. La plus grande préoccupation des chirurgiens
est le succès du traitement avec un taux de guérison élevé et un bon résultat esthétique. Il existe plusieurs méthodes de traitement, y compris la thérapie
au laser.
Les objectifs de la présente étude étaient d’évaluer la cicatrisation des plaies (récidive et résultat esthétique) après ablation chirurgicale et irradiation par
le mode superpulsé de laser CO2 du CBC.
Un total de 18 patients, âgés entre 58 et 71 ans, des deux sexes (7 hommes et 11 femmes) ont participe à l’étude. La masse tumorale a d’abord été
réséquée, puis le lit tumoral a été irradié en utilisant un laser CO2 pulsé de 5 à 8 W. Les plaies ont été laissées ouvertes pour une épithélisation secondaire.
Une récidive et des résultats esthétiques ont été observés après 1 an de suivi. L›âge moyen des participants était de 66 ans (entre 58 et 71 ans). La
taille moyenne (diamètre maximal de la lésion) était de 9,3 mm (entre 7,2 et 11,3 mm). 12 tumeurs étaient du type superficiel (66,6%) contre 6 tumeurs
(33,3%) du type nodulaire.
Le suivi à un an n’a montré aucune récidive. Une légère cicatrice a été retrouvée dans 3 cas (16,6%). Il n’y a eu aucune complication pendant la période
de cicatrisation.
Cette étude a montré que l’ablation chirurgicale combinée au laser CO2 superpulsé est une option efficace pour traiter le carcinome basocellulaire et pour
obtenir un taux de guérison élevé avec de bons résultats esthétiques.
Mots clés: chirurgie au laser - tumeur cutanée de la face - laser CO2 - carcinome basocellulaire.
IAJD 2020;11(2):94-99.
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Introduction
Basal cell carcinoma (BCC) is the
most common skin cancers in the face
region [1]. It’s a malignant cancer, arising from the basal layer of the epidermis with a slow growth rate and a
minor invasiveness; metastasis are
rare [2,3]. There are many clinical type
of BCC: superficial, nodular, infiltrative
[4]. Success of treatment depend on
the clearance of the tumor, the absence
of recurrence and the optimal esthetic
outcome [5].
Clinically, BCC appears as a flesh
pink plaque; 85% of the cases occur in
the face and neck region [6].
Several therapeutic protocols are
used in case of BCC, including surgical
excision [5,7-9], Mohs Micrographic
Surgery (MMS) [10,11], photodynamic therapy [12,13], cryosurgery [14],
electrocoagulation [15], application of
topical Imiquimod [16,17] and Laser
therapy [18-20].
The first gas Laser was produced
by Patel in 1964. Lasers emit long
wave infrared light at a wavelength of
10600 nm. This laser in its continuous
wave (CW) has the greatest power
compared to the other Lasers[21].
Water-containing tissue absorbs 90%
of the laser energy that causes tissue
vaporization and destroys connections
between cells. This biological interaction is the basis of the use of laser
CO2 when treating soft tissue lesions
[22]. Several studies used CO2 laser in
treatment of BCC and demonstrated
good outcomes [23-25].
The present study was carried out
to evaluate the healing of BCC (recurrence and esthetic outcome) after
surgical excision and irradiation with
superpulsed laser CO2 .

Materials and methods
A total of 18 patients who visited the
Department of Oral and Maxillofacial
Surgery at Tishreen Hospital between
November 2017 and February 2019,
and were diagnosed with BCC in the
face region by scraping biobsy were
included in the study. The participants

were of both gender (7 males and
11 females) with the age comprised
between 58-71 years. The medical history and clinical examination of the
lesions were recorded.
The inclusion criteria were: tumerous lesions diameter ≤ 12 mm, tumor
classification T1, no metastasis and no
metabolic diseases such diabetes.
Under local anesthesia (Lidocain
10%, 1:200 000 epinephrine), the tumor
was excised using a surgical blade #15
with 3 mm of surrounding skin as a
safety margin [26]. Incision around
the base of the lesion was performed,
and the lesion was then removed
completely. Tumor bed appeared as
a pink bleeding surface. Pressure for
5 minutes was exerted with a gauze
soaked in saline solution, to stop the
bleeding.
Laser power adjusted to 5-8 W,
superpulsed wave, spot size 3 mm were
used to irradiate the tumor bed after
excising the lesion. The wounds were
left open to secondary epithelization.
10.6 µm CO2 laser, guide wave
laser He-Ne laser 632 µm (Biopixel,
Bios, Italy) was used. Specifications
of the device are maximum output 45
W, the delivery system depending on
articulated arms and straight headpiece, with noncontact mode within
the procedure.
Antibiotic ointment was applied on
the wound after laser, and oral analgesic drugs were given directly after
surgery.
Recurrence and esthetic outcomes
were observed after 1 year follow- up.
Statistical analysis
Statistical package for Social
Science (SPSS version 25.0) software
was used to statistically analyze the
results. Level of significance was set at
0.05.

Results
18 BCC in the face region were
ablated with 3 mm of surrounding tissue, followed by vaporization of the
tumor bed.

The distribution of sample according to gender : 7 males (39%), 11
females (61%) . The mean age was 66
years (range 58-71 years).
The mean size ( maximal diameter of lesion) 9.3 mm with a range
7.2-11.3mm.
Superficial type of tumors was the
most common type (66.6%) (Fig. 1),
while nodular type was observed in 6
patients (33.3%) (Fig. 2).
The distribution of the lesions
location was: 5 (27.7%) on forehead, 5
(27.7%) on the temple, 4 (22.2%) on the
upper lip, 3 (16.6%) on the nasal alar
and 1 (5.5%) on the ear lobe.
The one-year follow showed no
recurrence. Slight scar was found in 3
cases (16.6%) There were no complications during the wound healing period.
There was a statistically significant
difference between the type of tumor
and the esthetic outcome (p>0.05).
The distribution of lesions and outcomes are presented in table 1.

Discussion
The successful treatment of BCC
depends on reliable ablation of the
entire cancerous lesions. Many therapeutic options are currently available,
such as surgical exision, Mohs micrographic surgery, curettage with and
without cautery, cryosurgery and laser
ablation.
Topical treatment with Imiquimod
is particularly indicated in cases of
genital and external perianal warts
(condyloma acuminata) in adults, in
small superficial basal cell carcinomas in adults and in clinically typical
actinic keratoses, non-hypertrophic,
non-hyperkeratotic of the face or scalp
in immunocompetent adults. The doctor in charge of the patient will choose
this first-line treatment when the size
or number of lesions limits the effectiveness and / or tolerance of cryotherapy and if other topical treatments are
contraindicated or less appropriate.
The surgical excision is the standard and the most effective treatment
of BCC of the skin. This technique
requires wide elimination of tissue,
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Patients

Diagnosis

Gender

Age

Location

Size

Recurrence

Esthetic
outcomes

1

Superficial BCC

F

58

Forehead

11.2

No

No scar

2

Superficial BCC

M

72

Nose alar

7.6

No

No scar

3

Nodular BCC

F

70

Upper lip

7.3

No

No scar

4

Nodular BCC

F

62

Forehead

8.2

No

No scar

5

Superficial BCC

M

71

Nose alar

10.5

No

No scar

6

Superficial BCC

F

61

Upper lip

11.3

No

No scar

7

Nodular BCC

M

71

Temple

8.1

No

No scar

8

Superficial BCC

M

71

Forehead

11

No

Slight scar

9

Nodular BCC

M

66

Upper lip

8.2

No

No scar

10

Superficial BCC

M

69

Temple

9.7

No

No scar

11

Superficial BCC

F

70

Nose alar

7.5

No

No scar

12

Superficial BCC

F

64

Temple

11

No

No scar

13

Nodular BCC

F

66

Upper lip

9.5

No

Slight scar

14

Superficial BCC

F

67

Forehead

7.2

No

No scar

15

Superficial BCC

F

59

Temple

10.3

No

No scar

16

Nodular BCC

F

69

Temple

8

No

No scar

17

Superficial BCC

F

60

Forehead

10.5

No

Slight scar

18

Superficial BCC

M

65

Ear lobe

9.4

No

No scar

Table 1: Patient details and outcomes of treatment.

Esthetic outcomes
No Scar

Tumor type
Sex

Lesion
location

Tumor size

Scar

N

N

%

N

%

Superficial

12

10

83.3

2

16.7

Nodular

6

5

83.3

1

16.7

Male

7

6

85.7

1

14.3

Female

11

9

81.8

2

18.2

Forehead

5

3

60

2

40

Temple

5

5

100

0

0

Upper lip

4

3

75

1

25

Nose alar

3

3

100

0

0

Ear lobe

1

1

100

0

0

<9

8

8

100

0

0

>9

10

7

75

3

25

Table 2: Distribution of esthetic outcomes.

P
9.6

0.002

0.036

0.95

4.26

0.921

2.91

0.09
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Fig. 1: Patient with superficial BCC on the forehead. A)
before treatment, B) after surgical excision and application of pulsed CO2 laser, C) at 1 year follow- up.

followed by skin grafts or local flaps
from surrounding skin to reconstruct
the wound bed , that often results in
less ideal esthetic outcomes [27]. In
addition, surgical excision of BCC can
be sometimes difficult especially in
sensitive anatomic areas like the lower
eyelid, leading to sever complications
such as distortion of anatomical landmarks [28].
The cancerous lesion is usually
excised with a safety margin. The value
of the safety margin varies in the different studies, a margin of 5mm being
considered as the safest for all the BCC

Fig. 2: Patient with nodular BCC on the temple; A)
before treatment, B) after surgical excision and application of pulsed CO2 laser , C) at 1 year follow- up.

[29]. However, the anatomical localization of the BCC might constrain the
choice of a wide safety margin. That’s
why a 3-4 mm safety margin or even
2 mm safety margin can be applied
in some cases with low-risk small
(<10mm) lesions [26].
The Mohs micrographic surgery
(MMS) consists of excising the BCC
lesion and histologically examining
the entire margin intraoperatively.
Depending on the result, if any margin is still involved, further excision
can be performed. This technique
permits accurate histologic analysis,

thus lower recurrence of the cancerous
lesion [28]. Despite these advantages,
this technique should be reserved to
high-risk or recurrent BCC due to its
time and cost limitations [29].
Curettage consists of scrapping off the tumor using a curette.
Electrocautery is then used to control
the bleeding and to destroy any residual tumor. This technique necessitates the biopsy of the lesion prior to
the curettage / electrocautery to cofirm
the diagnosis [30].
In cryosurgery, liquid nitrogen is
used to destruct the cancerous tissue.
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Biopsy and histologic analysis should
be done to confirm the diagnosis. This
technique is operator dependent. It
can be applied when treating low risk
BCC, either alone or combined to
curettage [31].
BCCs on the face can be also
managed non-surgically, using radiotherapy, topical 5% Imiquimod cream
(Aldara), photodynamic therapy or
topical 5-Fluorouracil 5% (Efudex) [29].
Carbon dioxide laser ablation has
been used in the treatment of BCCs
[31].
In this study, we evaluated the efficacy of surgically ablating BCC combined with the vaporization of bed tumor
using one pass of superpulsed CO2
laser.
Several studies have shown that
CO2 laser in superpulsed wave is an
effective alternative method for treating BCC with good esthetics outcomes
and less recurrence rate [24,32,33].
Usually, this method necessitates
several laser passes to eliminate all
tumorous cell. This depends on clinical appearance of the wound or the
histopathological examination result.
Horlock vaporized 21 superficial,
28 nodular and 2 infiltrative BCC with
multiple passes of superpulsed laser.
He demonstrated that Co2 laser is
effective in completely ablating all
superficial BCC and nodular types of
less than 10 mm diameter when it lasered the lower dermis or deeper [32].
Compolmi et al. used multiple passes to treat 140 patient
with superficial and nodular BCC.
Histopathological examination was
done three times (before, during and
at the end of treatment). After 1 year
follow-up no recurrence were observed
and no tumorous cells were detected
in biopsy after laser surgery [24].
Del Pozo and Rosende reported the
use of multiple passes of superpulsed
CO2 laser and focused mode to vaporize skin BCC in the face. After one year
follow-up, no recurrence was detected. However, three secondary complications in cosmetic outcomes were
presented: persistent and transitory

erythema, hypopigmented area and
textural alterations [34] .
In our study, we used superpulsed
CO2 laser to vaporize the wound bed
after entire ablation of the tumor, with
no wound closure; the surgical bed
was left to second epithelialization.
The advantages of this combination
lies in gain of histological test of the
excised lesion margin, and reduction
of aggressive manipulation in surrounding tissue to close the wound with
local flaps.
In a study of 113 BCC in the face
skin, 57% of the lesions were of the
nodular type. The tumor mass was
ablated with 2-5 mm of marginal tissue,
then the area exposed to 2 or 4 passes
of pulsed CO2 laser. Recurrence occurred in 6.3% of all lesions, and a good
to excellent outcomes was observed in
85.8%. All recurrent tumors showed a
complete cure after retreatment with
the same protocol [34] .
In the present study, no recurrence
were observed after 1 year follow-up.
The lesions showed a total cure, and
good cosmetic outcomes in 15 cases
(83.3% no scar). 3 cases showed slight
scar (16.6%), 2 on the forehead and 1
on the upper lip.
No statistically significant differences was found between esthetic
outcomes and gender of patient or
location of the lesion. However, there
was a statistically significant difference between esthetic outcomes and
the type of tumor. Although nodular
type is more aggressive in tissue, one
case showed slight scar versus 2 cases
of superficial type. This result might
be attributed to the incomplete surgical excision of the lesion before laser
irradiation.

Conclusion
The present study showed that surgical excision combined with superpulsed CO2 Laser in treatment of BCC
is an effective option to achieve high
cure rate and good esthetic outcomes.
This method is non aggressive compared with surgery alone.

However, this study presents many
limitations:
-
The number of participants
included in the study was small.
-
A one-year evaluation is a very
short follow-up in cancerology
even though BCC have good
prognosis.
This study could be considered a
pilot study. A future study with a larger
sample and a longer follow-up should
be programmed to confirm the reliability and the effectiveness of this protocol in the treatment of BCC.
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